Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks

WASHINGTON — Bulevirtide monotherapy was safe and effective at 72 weeks for patients with hepatitis D virus-related compensated cirrhosis, with virological and clinical responses increasing over time, according to data presented here.“Until now, administration of pegylated interferon has represented the only therapeutic option [for chronic hepatitis D], but was characterized by suboptimal viral response and significant side effects,” Elisabetta Degasperi, MD, PhD, from the Division of Gastroenterology and Hepatology at the Foundation IRCCS Ca’ Granda Ospedale MaggioreRead More

Generated by Feedzy